Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Perinatal Diagnosis of GIT Anomalies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03514940
Recruitment Status : Recruiting
First Posted : May 3, 2018
Last Update Posted : January 9, 2019
Sponsor:
Collaborators:
Kasr El Aini Hospital
National Research Center, Egypt
Information provided by (Responsible Party):
Mahmoud Alalfy, Aljazeera Hospital

Brief Summary:
fetal gastro intestinal abnormalities can be accurately diagnosed in second trimester

Condition or disease Intervention/treatment
Fetal Anomalies Diagnostic Test: ultrasound

Detailed Description:
prenatal diagnosis of these anomalies allows for early postnatal interventions and implementation of treatment options

Layout table for study information
Study Type : Observational
Estimated Enrollment : 130 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Perinatal Diagnosis of Fetal GIT Anomalies
Actual Study Start Date : May 2, 2018
Estimated Primary Completion Date : April 3, 2019
Estimated Study Completion Date : April 7, 2019

Intervention Details:
  • Diagnostic Test: ultrasound
    second trimester us scan will be made to pregnant women


Primary Outcome Measures :
  1. The number of participants who will be diagnosed to have GIT anomalies [ Time Frame: within 5 moths ]
    GIT anomalies that will be diagnosed by US and confirmed postnatal and managed operatively



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   pregnant females
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
pregnant ladies either primi or multigravida
Criteria

Inclusion Criteria:

  • pregnant women either primi or multigravida
  • pregnant in 18- 24 weeks

Exclusion Criteria:

  • first trimester pregnant ladies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03514940


Contacts
Layout table for location contacts
Contact: Mahmoud Alalfy 01002611058 mahmoudalalfy@ymail.com

Locations
Layout table for location information
Egypt
Algazeerah Recruiting
Giza, Egypt
Contact: Mahmoud Alalfy, master    +201002611058    mahmoudalalfy@ymail.com   
Contact: Ahmed Elgazzar, M.D    +201014005959      
Principal Investigator: Mahmoud Alalfy, master         
Sponsors and Collaborators
Aljazeera Hospital
Kasr El Aini Hospital
National Research Center, Egypt
Investigators
Layout table for investigator information
Principal Investigator: Mahmoud Alalfy, M.s.c Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt

Layout table for additonal information
Responsible Party: Mahmoud Alalfy, Assistant Researcher , National Research centre and Specialist of Obstetrics and Gynecology in Aljazeerah hospital, Aljazeera Hospital
ClinicalTrials.gov Identifier: NCT03514940     History of Changes
Other Study ID Numbers: GIT
First Posted: May 3, 2018    Key Record Dates
Last Update Posted: January 9, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: results will be published

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Congenital Abnormalities